The leading European professional organisation for medical oncology (the European Society of Medical Oncology, ESMO), in collaboration with the American Society of Clinical Oncology (ASCO), published the 2016 edition of the ESMO/ASCO Recommendations for a Global Curriculum (GC) in Medical Oncology, a set of common guidelines to offer a global perspective of the clinical training required for physicians to qualify as medical oncologists. ESMO used its recent and well-attended conference in October in Copenhagen Denmark in October, to announce the release of its Curriculum.
Professor Sarah Coupland, who was part of the GC writing group as a cancer- and molecular pathologist, added: “ This is a unique work, put together by experts involved in cancer patient care and cancer diagnostics. By drawing up recommendations for training in this field, we are aiming for high quality and consistency in cancer teaching across the globe, and thereby help address inequalities and future proofing in cancer patient care".
The integration of molecular pathology to determine the presence of biomarkers as criteria to select appropriate new therapies is one of the most appreciable novelties now included in the 2016 edition of the GC, making it a fundamental reference for internationally recognised standards for medical oncology training.
Professor Sarah Coupland added: “Molecular pathology is essential for understanding cancer development, and is becoming integral for all cancer diagnostics, prognostication, as well as treatment response prediction and monitoring". She adds that this feeds very well into various initiatives underway in the UK, including the NCRI CM-Path programme (www.ncri.org.uk/initiatives/pathology/), in which Prof. Coupland is also involved.
Professor Sarah Coupland, who was part of the GC writing group as a cancer- and molecular pathologist, added: “ This is a unique work, put together by experts involved in cancer patient care and cancer diagnostics. By drawing up recommendations for training in this field, we are aiming for high quality and consistency in cancer teaching across the globe, and thereby help address inequalities and future proofing in cancer patient care".
The integration of molecular pathology to determine the presence of biomarkers as criteria to select appropriate new therapies is one of the most appreciable novelties now included in the 2016 edition of the GC, making it a fundamental reference for internationally recognised standards for medical oncology training.
Professor Sarah Coupland added: “Molecular pathology is essential for understanding cancer development, and is becoming integral for all cancer diagnostics, prognostication, as well as treatment response prediction and monitoring". She adds that this feeds very well into various initiatives underway in the UK, including the NCRI CM-Path programme (www.ncri.org.uk/initiatives/pathology/), in which Prof. Coupland is also involved.
